文献速递炎症性肠病

克罗恩病患者在获益与风险偏好及缓解时间等值上的差异

Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-05-14

该在线陈述性偏好调查纳入812例克罗恩病患者,量化其对不同治疗结局和不良事件的偏好,并评估潜在类别异质性。潜在类别分析显示3个 distinct 组别:避免活动性症状(61%)、避免使用糖皮质激素(25%)、避免癌症/感染/手术风险(14%)。各潜在类别的缓解时间等值与总体样本均值存在显著差异。

要点

  • 克罗恩病患者治疗偏好存在显著异质性,可分为3个潜在类别。
  • 61%患者选择治疗时主要受避免活动性症状影响。
  • 25%患者主要避免使用糖皮质激素,14%主要避免癌症、感染或手术风险。

核心结论

  • 在克罗恩病患者的在线调查中,发现对药物疗效和伤害风险的偏好存在实质性异质性。
  • 医生和监管者不应假设所有患者具有均值偏好,否则可能导致健康技术评估模型出现显著差异。

研究设计与样本

  • 在线陈述性偏好调查,纳入克罗恩病与结肠炎基金会 Partners 队列(IBD Partners)中812例克罗恩病患者。
  • 患者获得关于活动性疾病症状和严重程度、糖皮质激素治疗持续时间以及严重感染、癌症和手术风险的信息。
  • 要求患者假设其治疗无效并选择替代疗法,主要结局为特定持续时间症状严重程度或治疗相关风险的缓解时间等值(RTE)。
  • 采用潜在类别选择模型识别具有主导治疗结局偏好的患者组别及相关患者特征。

主要发现

  • 潜在类别分析显示3个 distinct 的调查应答者组别:避免活动性症状(61%)、避免使用糖皮质激素(25%)、避免癌症、感染或手术风险(14%)。
  • 类别归属与年龄、性别、平均短克罗恩病活动指数评分及糖皮质激素避免相关。
  • 各潜在类别的RTE与总体样本的平均RTE存在显著差异,其中症状避免类别最接近总体样本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with Crohn's disease (CD) must make decisions about their treatment. We aimed to quantify patients' preferences for different treatment outcomes and adverse events. We also evaluated the effects of latent class heterogeneity on these preferences. METHODS: An online stated-preference survey was completed by 812 individuals with CD in the Crohn's and Colitis Foundation Partners cohort (IBD Partners). Patients were given information on symptoms and severity of active disease; duration of therapy with corticosteroids; and risks of serious infection, cancer and surgery. Patients were asked to assume that their treatment was not working and to choose an alternative therapy. The primary outcome was remission-time equivalents (RTE) of a given duration of symptom severity or treatment-related risk. Latent class choice models identified groups of patients with dominant treatment-outcome preferences and associated patient characteristics with these groups. RESULTS: Latent class analysis demonstrated 3 distinct groups of survey responders whose choices were strongly influenced by avoidance of active symptoms (61%), avoidance of corticosteroid use (25%), or avoidance of risks of cancer, infection or surgery (14%) when choosing a therapy. Class membership was correlated with age, sex, mean short CD activity index score and corticosteroid avoidance. RTEs in each latent class differed significantly from the mean RTEs for the overall sample, although the symptom-avoidant class most closely approximated the overall sample. CONCLUSIONS: In an online survey of patients with CD, we found substantial heterogeneity in preference for medication efficacy and risk of harm. Physicians and regulators should therefore not assume that all patients have mean-value preferences-this could result in significant differences in health-technology assessment models.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bewtra M, Reed SD, Johnson FR, et al. Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents. Clin Gastroenterol Hepatol. 2019. PMID: 31100456. doi:10.1016/j.cgh.2019.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。